Profile data is unavailable for this security.
About the company
Faron Pharmaceuticals Oy is a Finland-based clinical stage biopharmaceutical company. The company has three drug candidates all based on mastering immune modulation and, as a result, tackling unmet needs in cancer, preventing organ damage and treating blood count abnormalities. The Company's goal is to build future immunotherapy, i.e., to bring new treatments to patients by affecting the immune system. Faron’s drug candidate, Traumakine, is a drug developed by the Company to prevent multi-organ damage and excessive inflammatory responses. Another drug candidate, Haematokine, promotes the expansion of bone marrow stem cells. It is being developed, e.g., for the treatment of chemotherapyinduced neutropenia (CIN). In neutropenia patients have less blood cells called neutrophils than normal due to cancer treatment.
- Revenue in GBP (TTM)0.00
- Net income in GBP-26.91m
- Incorporated2006
- Employees25.00
- LocationFaron Pharmaceuticals OyJoukahaisenkatu 6TURKU 20520FinlandFIN
- Phone+358 24695151
- Fax+358 24695152
- Websitehttps://www.faron.com/
| Holder | Shares | % Held |
|---|---|---|
| Keskin�inen Ty�el�kevakuutusyhti� Varmaas of 27 Aug 2025 | 5.13m | 4.49% |
| Fj�rde AP-fondenas of 27 Aug 2025 | 3.29m | 2.88% |
| OP Asset Management Ltd.as of 30 Jun 2025 | 2.74m | 2.39% |
| Sp-Fund Management Co. Ltd.as of 30 Jan 2026 | 1.58m | 1.38% |
| Heights Capital Management, Inc.as of 27 Aug 2025 | 857.32k | 0.75% |
| Veritas Pension Insurance Co. Ltd.as of 27 Aug 2025 | 805.74k | 0.70% |
| Mandarine Gestion SAas of 30 Jun 2025 | 389.81k | 0.34% |
| Danske Bank A/S (Investment Management Finland)as of 30 Dec 2025 | 327.42k | 0.29% |
| Fondita Fund Management Co. Ltd.as of 27 Aug 2025 | 193.28k | 0.17% |
| Canaccord Genuity Wealth Ltd.as of 30 Sep 2025 | 159.58k | 0.14% |
